Protein Kinase A Activity Controls the Regulation of T-type CaV3.2 Channels by Gβγ DimersS
Low voltage-activated (LVA), T-type, calcium channels mediate diverse biological functions and are inhibited by Gβγ dimers, yet the molecular events required for channel inhibition remain unknown. Here, we identify protein kinase A (PKA) as a molecular switch that allows Gβ 2 γx dimers to effect vol...
Saved in:
Published in | The Journal of biological chemistry Vol. 284; no. 12; pp. 7465 - 7473 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
American Society for Biochemistry and Molecular Biology
20.03.2009
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Low voltage-activated (LVA), T-type, calcium channels mediate diverse
biological functions and are inhibited by Gβγ dimers, yet the
molecular events required for channel inhibition remain unknown. Here, we
identify protein kinase A (PKA) as a molecular switch that allows
Gβ
2
γx dimers to effect voltage-independent inhibition of
Ca
v
3.2 channels. Inhibition requires phosphorylation of
Ser
1107
, a critical serine residue on the II-III loop of the
channel pore protein. S1107A prevents inhibition of unitary currents by
recombinant Gβ
2
γ
2
dimers but does not disrupt
dimer binding nor change its specificity. Gβγ dimers released upon
receptor activation also require PKA activity for their inhibitory actions.
Hence, dopamine inhibition of Ca
v
3.2 whole cell current is
precluded by Gβγ-scavenger proteins or a peptide that blocks PKA
catalytic activity. Fittingly, when used alone at receptor-selective
concentrations, D
1
or D
2
agonists do not elicit channel
inhibition yet together synergize to inhibit Ca
v
3.2 channel
currents. We propose that a dual-receptor regulatory mechanism is used by
dopamine to control Ca
v
3.2 channel activity. This mechanism, for
example, would be important in aldosterone producing adrenal glomerulosa cells
where channel dysregulation would lead to overproduction of aldosterone and
consequent cardiac, renal, and brain target organ damage. |
---|---|
Bibliography: | To whom correspondence should be addressed: 1300 Jefferson Park Ave, Charlottesville, VA 22908. Fax: 434-982-3878; E-mail: pqb4b@virginia.edu. This work was supported, in whole or in part, by National Institutes of Health Grant HL36977 (to P. Q. B.). This work was also supported by American Heart Association Grant AHA 053535ON (to W. E. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Supported by a postdoctoral fellowship from the American Heart Association Mid-Atlantic Affiliate. The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2. |
ISSN: | 0021-9258 1083-351X |
DOI: | 10.1074/jbc.M808049200 |